Breaking News Instant updates and real-time market news.

GILD

Gilead

$81.82

1.03 (1.27%)

, ABBV

AbbVie

$113.08

(0.00%)

09:44
02/15/18
02/15
09:44
02/15/18
09:44

Lawmakers to push for hep C drug patents being taken, Capitol Forum says

Representative Ro Khanna and 10 other Congress members plan to send a letter urging HHS Secretary Alex Azar to use his legal authority to take patents for hepatitis C virus drugs, according to The Capitol Forum, citing word from Khanna's office. Makers of hep C drugs include Gilead (GILD) and AbbVie (ABBV). Reference Link

GILD

Gilead

$81.82

1.03 (1.27%)

ABBV

AbbVie

$113.08

(0.00%)

  • 16

    Feb

  • 21

    Feb

  • 08

    Mar

GILD Gilead
$81.82

1.03 (1.27%)

01/31/18
JEFF
01/31/18
NO CHANGE
JEFF
Jefferies sees neutral impact on Biotech from State of the Union
Jefferies analyst Michael Yee sees a net neutral impact on Biotech stocks from President Trump's State of the Union speech last night. During the speech, Trump made comments about making lower drug prices a "priority" for the year, Yee tells investors in a research not titled "Drug Pricing Comments Not New or Surprising - But a Reminder of Rhetoric." The President, however, also commented on broader access to novel clinical trial drugs, Yee points out. After a "strong biotech rally" in January, the analyst assumes the sector, "at some point," will have some relative near-term pullback either on uncertainty about Trump commentary or some consolidation. Some of the analyst's Buy-rated names include AbbVie (ABBV), Amgen (AMGN), Eli Lilly (LLY) and Gilead Sciences (GILD).
02/07/18
SBSH
02/07/18
NO CHANGE
Target $105
SBSH
Buy
Gilead should be bought ahead of pipeline catalysts, says Citi
Citi analyst Robyn Karnauskas raised her price target for Gilead Sciences to $105 from $103 following last night's Q4 results. The analyst recommends buying the stock ahead of pipeline catalysts and keeps a Buy rating on the name. The base business seems to be stabilizing while gene therapy could be a potential growth area, Karnauskas tells investors in a post-earnings research note.
02/08/18
MSCO
02/08/18
NO CHANGE
MSCO
Equal Weight
Gilead Biktarvy approval, Glaxo patent suit not surprising, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison said investors expected Gilead (GILD) to receive FDA approval for its once-daily single tablet regimen to treat HIV-1 infection, now named Biktarvy, so he would expect limited impact on the stock from the news. He also said GlaxoSmithKline's (GSK) filing of patent infringement litigation alleging that Biktarvy infringes on ViiV's dolutegravir is not a surprise given prior comments by GSK and he would expect this to work through the courts. Harrison, who added that Biktarvy's clean label is a positive, keeps an Equal Weight rating on Gilead shares.
02/09/18
WELS
02/09/18
NO CHANGE
WELS
Outperform
Gilead should be bought on patent challenge weakness, says Wells Fargo
Wells Fargo analyst Jim Birchenough recommends buying Gilead Sciences on weakness following a patent infringement lawsuit against recently approved single tablet regimen Biktarvy for HIV. The analyst believes that Biktarvy patents will hold up to challenge and that the lawsuit will not impact launch or longer term value creation. He remains confident in Gilead's growth beyond "trough earnings" in 2018 and keeps an Outperform rating on the stock.
ABBV AbbVie
$113.08

(0.00%)

01/30/18
01/30/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AbbVie (ABBV) downgraded to Underperform from Market Perform by analyst Alex Arfaei, who said the risk/reward has "meaningfully changed" after the rise in the stock price, adding that the new focus on fundamentals beyond the benefits of tax reform suggests "significant price erosion in immunology driven by interchangeable biosimilar anti-TNFs, and lower effectiveness of the 'Rebate Trap' to block access to cheap biosimilars". 2. iRobot (IRBT) downgraded to Neutral from Buy at Sidoti by analyst Frank Camma, who cited valuation as shares approach his $98 price target. 3. Horizon Global (HZN) downgraded to Market Perform from Outperform at BMO Capital by analyst Gerrick Johnson, who said that while he still sees "strong demand in key end markets," operation execution, rising input costs, and high debt levels are concerning. The analyst added that the company may have "lost the faith of investors" after a 30% drop in the stock price following the guidance cut. 4. Yum! Brands (YUM) downgraded to Neutral from Buy at Nomura Instinet by analyst Mark Kalinowshi, who cited valuation and concerns a possible 2018 slowdown in U.S. same-store-sales. 5. Alaska Air (ALK) downgraded to Underweight from Neutral at JPMorgan by analyst Jamie Baker, who noted that the airline is the only name where he had to cut his 2019 estimates. He also believes the company "remains in the United crosshairs in San Francisco." The analyst also downgraded Southwest (LUV) to Neutral from Overweight, and said he believes better relative value exists elsewhere in the Airlines sector. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/02/18
ARGS
02/02/18
NO CHANGE
Target $145
ARGS
Buy
AbbVie price target raised to $145 from $120 at Argus
Argus analyst David Toung raised his price target on AbbVie to $145 and kept his Buy rating after a "solid" Q4 earnings report that also included a substantial boost from lower tax rates. Toung says AbbVie is likely to submit more applications for new products and expanded indications of existing drugs this year as it develops new growth drivers such as Imbruvica and Mavyret to complement the current large contribution from Humira.
02/05/18
JEFF
02/05/18
NO CHANGE
Target $25
JEFF
Hold
Acorda remains takeover candidate after competitor data, says Jefferies
Jefferies analyst Michael Yee believes the positive Phase III topline results from Acorda Therapeutics (ACOR) competitor Sunovion for APL-130277 in Parkinson's patients came in as expected. While APL-130277 data compares favorably over Inbrija's 3.92 point difference at week 12, Yee cautions to compare directly head-to-head since patient baseline characteristics could be different. Acorda remains a "reasonably likely" acquisition candidate in 2018 given its $300M-$500M-plus Parkinson's asset Inbrija, Yee tells investors in a research note. The analyst does not think Biogen (BIIB) should buy the company, but sees other potential suitors in AbbVie (ABBV), Allergan (AGN), Mitsubishi, Roche (RHHBY) and Shire (SHPG). He believes a takeover price could be north of $2B. Yee keeps a Hold rating on Acorda with a $25 price target.

TODAY'S FREE FLY STORIES

PZZA

Papa John's

$55.29

3.26 (6.27%)

12:40
06/20/18
06/20
12:40
06/20/18
12:40
Options
Timely sweep buyer of Papa John's weeklys »

Timely sweep buyer of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:40
06/20/18
06/20
12:40
06/20/18
12:40
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

AAL

American Airlines

$42.29

0.78 (1.88%)

12:37
06/20/18
06/20
12:37
06/20/18
12:37
Hot Stocks
American asks government not to use planes for separated children »

American released a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

AEP

American Electric

$66.87

(0.00%)

12:30
06/20/18
06/20
12:30
06/20/18
12:30
Hot Stocks
SWEPCO says LPSC approves proposed Wind Catcher Energy Connection project »

Southwestern Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KO

Coca-Cola

$43.44

-0.16 (-0.37%)

12:25
06/20/18
06/20
12:25
06/20/18
12:25
Conference/Events
The Executives' Club of Chicago to hold a meeting »

The Executives Club of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

SPY

SPDR S&P 500 ETF Trust

$276.40

0.92 (0.33%)

12:20
06/20/18
06/20
12:20
06/20/18
12:20
Options
Aggressive call spreads in SPYders »

Aggressive call spreads…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$202.58

5.12 (2.59%)

12:17
06/20/18
06/20
12:17
06/20/18
12:17
Hot Stocks
Facebook tests 'subscription groups' for administrators »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
06/20/18
06/20
12:17
06/20/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
06/20/18
06/20
12:16
06/20/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIG

Signet Jewelers

$60.04

2.91 (5.09%)

12:15
06/20/18
06/20
12:15
06/20/18
12:15
Options
Signet Jewelers put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$276.27

0.79 (0.29%)

12:14
06/20/18
06/20
12:14
06/20/18
12:14
Technical Analysis
Technical Take: SPDR S&P 500 ETF round-trips to session highs at midday »

The SPDR S&P 500 ETF…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$276.27

0.79 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSRO

Tesaro

$44.08

4.04 (10.09%)

, CLVS

Clovis

$47.48

1.74 (3.80%)

12:11
06/20/18
06/20
12:11
06/20/18
12:11
Recommendations
Tesaro, Clovis analyst commentary  »

SunTrust analysis yields…

TSRO

Tesaro

$44.08

4.04 (10.09%)

CLVS

Clovis

$47.48

1.74 (3.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATUS

Altice USA

$17.52

0.42 (2.46%)

12:09
06/20/18
06/20
12:09
06/20/18
12:09
Hot Stocks
Altice says U.S .mobile service available in 2019,names Jean-Charles Nicolas SVP »

Altice USA announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOXA

21st Century Fox

$47.86

3.15 (7.05%)

, DIS

Disney

$106.00

-0.2 (-0.19%)

12:01
06/20/18
06/20
12:01
06/20/18
12:01
General news
On The Fly: Top stock stories at midday »

Stocks opened higher as…

FOXA

21st Century Fox

$47.86

3.15 (7.05%)

DIS

Disney

$106.00

-0.2 (-0.19%)

CMCSA

Comcast

$32.77

-0.04 (-0.12%)

GE

General Electric

$12.86

-0.105 (-0.81%)

WBA

Walgreens Boots Alliance

$67.72

3.11 (4.81%)

SBUX

Starbucks

$52.40

-5.03 (-8.76%)

ORCL

Oracle

$42.86

-3.43 (-7.41%)

FDX

FedEx

$253.85

-4.495 (-1.74%)

AMZN

Amazon.com

$1,755.30

19.56 (1.13%)

JPM

JPMorgan

$108.08

0.5 (0.46%)

BRK.A

Berkshire Hathaway

$285,450.00

-810 (-0.28%)

I

Intelsat

$19.52

3.46 (21.54%)

SYNA

Synaptics

$54.39

5.58 (11.43%)

DLGNF

Dialog Semiconductor

$0.00

(0.00%)

FOX

21st Century Fox

$47.24

2.96 (6.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 20

    Jun

  • 22

    Jun

  • 28

    Jun

  • 09

    Jul

  • 10

    Jul

  • 12

    Jul

  • 13

    Jul

  • 20

    Sep

  • 21

    Sep

  • 12

    Oct

T

AT&T

$32.02

-0.37 (-1.14%)

12:01
06/20/18
06/20
12:01
06/20/18
12:01
Periodicals
AT&T plans to acquire all of Otter Media, Recode reports »

AT&T intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHI

Sinopec Shanghai

$63.23

-4.37 (-6.46%)

12:00
06/20/18
06/20
12:00
06/20/18
12:00
Hot Stocks
Sinopec Shanghai falls -6.4% »

Sinopec Shanghai is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$42.91

-3.38 (-7.30%)

12:00
06/20/18
06/20
12:00
06/20/18
12:00
Hot Stocks
Oracle falls -7.3% »

Oracle is down -7.3%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEW

Puxin Limited

$26.90

-2.8 (-9.43%)

12:00
06/20/18
06/20
12:00
06/20/18
12:00
Hot Stocks
Puxin Limited falls -10.9% »

Puxin Limited is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATU

Actuant

$28.40

2.45 (9.44%)

12:00
06/20/18
06/20
12:00
06/20/18
12:00
Hot Stocks
Actuant rises 9.7% »

Actuant is up 9.7%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 27

    Jun

WGO

Winnebago

$45.75

5.35 (13.24%)

12:00
06/20/18
06/20
12:00
06/20/18
12:00
Hot Stocks
Winnebago rises 13.6% »

Winnebago is up 13.6%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

HAL

Halliburton

$45.85

-0.25 (-0.54%)

12:00
06/20/18
06/20
12:00
06/20/18
12:00
Options
Second day of interest in Halliburton Aug 50 calls »

Second day of interest in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

I

Intelsat

$19.50

3.44 (21.42%)

12:00
06/20/18
06/20
12:00
06/20/18
12:00
Hot Stocks
Intelsat rises 21.4% »

Intelsat is up 21.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DAL

Delta Air Lines

$54.40

0.625 (1.16%)

11:57
06/20/18
06/20
11:57
06/20/18
11:57
Conference/Events
National Press Club to host a luncheon meeting »

Luncheon Meeting with Ed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 29

    Jun

11:55
06/20/18
06/20
11:55
06/20/18
11:55
General news
Treasury Action: the 7s-10s spread is modestly wider at 4.1 bps »

Treasury Action: the…

11:55
06/20/18
06/20
11:55
06/20/18
11:55
General news
Euro$ interest rate futures are slightly lower »

Euro$ interest rate…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.